Ophthalmic

North American Ophthalmic Packaging Market (2020 to 2030) - Industry Analysis, Size, Share, Growth, Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Packaging, Pharmaceutical, Health, Manufacturing, Product management, Labels, Packaging and labeling, Ophthalmic

Which is the most preferred material type for ophthalmic packaging in the North America market?

Key Points: 
  • Which is the most preferred material type for ophthalmic packaging in the North America market?
  • Which dose holds maximum market share in the North America ophthalmic packaging market?
  • The study enumerates vital market dynamics such as key drivers, challenges, and trends, along with opportunities in the North America ophthalmic packaging market.
  • Furthermore, forecast factors and forecast scenarios of the ophthalmic packaging market have been covered in the report to understand future prospects of the market.

PanOptica Announces Licensing Agreement with Zhaoke Ophthalmology for PAN-90806 for the Treatment of Neovascular Eye Diseases in China, South Korea, and Southeast Asia

Retrieved on: 
Thursday, June 17, 2021
General Health, Health, Science, Research, Optical, Macular degeneration, Senescence, Ophthalmology, Ophthalmic, Vision, PAN-90806, PanOptica, Zhaoke Ophthalmology Limited, PAN-90806, PANOPTICA, ZHAOKE OPHTHALMOLOGY LIMITED

PanOptica, Inc. today confirms the licensing agreement with Zhaoke Ophthalmology Limited (HKEX Stock Code: 6622.HK) to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, in China, South Korea, and southeast Asia.

Key Points: 
  • PanOptica, Inc. today confirms the licensing agreement with Zhaoke Ophthalmology Limited (HKEX Stock Code: 6622.HK) to develop and commercialize PAN-90806, an investigational topical eye drop for the treatment of neovascular eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, in China, South Korea, and southeast Asia.
  • PanOptica will support Zhaoke Ophthalmology through the provision of its expertise and know-how, as well as its existing supply of investigational product and/or active pharmaceutical ingredient.
  • Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to the research, development, and commercialization of therapies that address significant unmet medical needs.
  • Zhaoke Ophthalmology has received strong endorsement from blue-chip pre-IPO investors, including GIC, Hillhouse Capital, TPG, Loyal Valley Capital, OrbiMed, and Aier Eye Hospital.

Visionology Acquires Exclusive Worldwide License to SPARCS Contrast Sensitivity Testing Technology

Retrieved on: 
Thursday, June 3, 2021
Accuracy and precision, Bioinformatics, Cheminformatics, Sensitivity and specificity, Statistical classification, Ophthalmic, Academic disciplines

NASHVILLE, Tenn., June 03, 2021 (GLOBE NEWSWIRE) -- Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq:HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its SPARCS technology available on Visionologys direct-to-consumer eyecare platform, Visionology.com .

Key Points: 
  • NASHVILLE, Tenn., June 03, 2021 (GLOBE NEWSWIRE) -- Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq:HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its SPARCS technology available on Visionologys direct-to-consumer eyecare platform, Visionology.com .
  • The need for SPARCS and other tools to help with the self-diagnosis of eye disease has never been greater.
  • The SPARCS contrast sensitivity test, which has undergone extensive testing in clinical trials, is a new eye test that focuses specifically on the ability to perceive contrast between light and dark.
  • For more information on the SPARCS contrast sensitivity test, go to sparcscontrastcenter.com .

Upsher-Smith And Rafarm Announce Launch Of Moxifloxacin Ophthalmic Solution, USP 0.5%

Retrieved on: 
Thursday, May 27, 2021
Chemical compounds, Drugs, Health care, Maple Grove, Minnesota, Upsher-Smith Laboratories, Moxifloxacin, Food and Drug Administration, Ophthalmic, Abbreviated New Drug Application, Anda, New Drug Application

MAPLE GROVE, Minn. and ATHENS, May 27, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and Rafarm S.A. (Rafarm) today announced the U.S. commercial launch of Moxifloxacin Ophthalmic Solution, USP 0.5% following a recent abbreviated new drug application (ANDA)approval by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MAPLE GROVE, Minn. and ATHENS, May 27, 2021 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and Rafarm S.A. (Rafarm) today announced the U.S. commercial launch of Moxifloxacin Ophthalmic Solution, USP 0.5% following a recent abbreviated new drug application (ANDA)approval by the U.S. Food and Drug Administration (FDA).
  • In 2018, Upsher-Smith and Rafarm entered into a partnership agreement to develop and distribute six ophthalmic and otic ANDA products.
  • "The launch of Moxifloxacin is significant because it represents a series of firsts for Upsher-Smith," said Rusty Field, President and CEO of Upsher-Smith.
  • "It is not only our first ophthalmic product to enter the market, but also the first product resulting from our partnership with Rafarm.

Nevakar Announces Formation Of Ophthalmic Company, Vyluma

Retrieved on: 
Tuesday, May 25, 2021
Medication, Pharmaceutical industry, Ophthalmic, Natural sciences

BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ --Nevakar Inc. ("Nevakar"), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.

Key Points: 
  • BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ --Nevakar Inc. ("Nevakar"), a privately held biopharmaceutical company, today announces the establishment of Vyluma Inc., a newly formed company with a focus on the development and commercialization of therapies to treat ophthalmic diseases.
  • At inception Vyluma will operate as a wholly owned subsidiary of Nevakar Inc.
    Vyluma will focus on first-in-class and best-in-class ophthalmic pharmaceutical therapies, with an emphasis on refractive errors.
  • With the establishment of Vyluma, our ophthalmic portfolio will have a dedicated team of professionals focused on assuring Vyluma meets its commitment to patients, prescribers, shareholders and other key constituents."
  • Nevakar Inc. is a privately held, late-stage biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas.

Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops

Retrieved on: 
Monday, May 17, 2021
Medical specialties, Drugs, Health care, Ciclosporin, Immunosuppressants, Ophthalmology, Ophthalmic, Optometry

No adverse events were observed.\nImprimisRx is one of the nation\xe2\x80\x99s leading ophthalmic-focused prescription pharmaceutical companies, serving thousands of ophthalmologists and optometrists in all 50 states, with 40 proprietary ophthalmic formulations.

Key Points: 
  • No adverse events were observed.\nImprimisRx is one of the nation\xe2\x80\x99s leading ophthalmic-focused prescription pharmaceutical companies, serving thousands of ophthalmologists and optometrists in all 50 states, with 40 proprietary ophthalmic formulations.
  • Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
  • Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial.
  • A Clinical Phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease.

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership that Will Ensure Greater Access to Important Eye Care Medicines in Russia

Retrieved on: 
Monday, May 17, 2021
Life sciences, Bausch Health, S&P/TSX 60, Medication, Ophthalmic, Optometry, Health care, Biotechnology

"By joining forces SIFI will strengthen its global footprint and establish its presence in Russia, one of the fastest growing pharmaceutical markets in the world, and will enable Russian eye care doctors to address a wide variety of ophthalmic disorders, delivering significant benefits to Russian patients.

Key Points: 
  • "By joining forces SIFI will strengthen its global footprint and establish its presence in Russia, one of the fastest growing pharmaceutical markets in the world, and will enable Russian eye care doctors to address a wide variety of ophthalmic disorders, delivering significant benefits to Russian patients.
  • "\n"Bausch Health is pleased to partner with SIFI, because together we can ensure Russian eye health doctors and their patients have greater access to these important ophthalmic medications," said Cees Heiman,Vice President Europe/Russia Pharmaceuticals, Bausch Health.\nSIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935.
  • SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases.
  • SIFI is committed to improve patients\' quality oflife through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey.\n'

EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 12, 2021
Ophthalmology, Health, Clinical medicine, Eye drop, Ophthalmic drug administration, Dry eye syndrome, Ophthalmic, Cost, Conjunctivitis, Argus Panoptes

PP-001 has been successfully formulated as an ophthalmic eye drop for conjunctivitis and dry eye disease (\xe2\x80\x9cDED\xe2\x80\x9d).

Key Points: 
  • PP-001 has been successfully formulated as an ophthalmic eye drop for conjunctivitis and dry eye disease (\xe2\x80\x9cDED\xe2\x80\x9d).
  • The increase of $0.342 million was primarily due to increases in personnel related costs from the Panoptes acquisition, OBG manufacturing costs, and development costs for PP-001.
  • EyeGate\xe2\x80\x99s results may also be affected by factors of which EyeGate is not currently aware.
  • The forward-looking statements in this press release speak only as of the date of this press release.

Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico

Retrieved on: 
Wednesday, May 5, 2021
NicOx, Grin, Ophthalmic

Laboratorios Grin are leaders in ophthalmology in Mexico, with over 60 years of experience in this field, and so are the ideal partner for Nicox to commercialize our ZERVIATE in this market.

Key Points: 
  • Laboratorios Grin are leaders in ophthalmology in Mexico, with over 60 years of experience in this field, and so are the ideal partner for Nicox to commercialize our ZERVIATE in this market.
  • With in-house manufacturing and regulatory capabilities, Laboratorios Grin will be able to manage all aspects of the process to approve ZERVIATE, relying on the U.S. filing to support their regulatory submission.\xe2\x80\x9d\nGrin is granted rights to develop and commercialize cetirizine ophthalmic solution, 0.24% in Mexico.
  • Nicox will receive an undisclosed license fee and potential milestone payments linked to regulatory approval and sales, and is eligible to receive double digit royalties on net sales of ZERVIATE.
  • Grin will be responsible, at its own cost, for the development, manufacturing and the commercialization of ZERVIATE in Mexico.\nLuis Guillermo Cort\xc3\xa9s, VP and Managing Director Laboratorios Grin, said: \xe2\x80\x9cWe are thrilled to partner with Nicox for ZERVIATE and to bring to Mexico state-of-the-art innovation for patients suffering from allergic conjunctivitis.

Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting

Retrieved on: 
Thursday, April 29, 2021
Vision, Optometry, Health care, Health, Contact lenses, Bausch & Lomb, Bausch, Loteprednol, Prednisolone, Ophthalmic, Eye care professional, Lomb

We are proud to support these important studies and share the latest findings with eye care professionals during the ARVO meeting.

Key Points: 
  • We are proud to support these important studies and share the latest findings with eye care professionals during the ARVO meeting.
  • Bausch + Lomb announced the FDA approval of ClearVisc in April.
  • Papour et al.\n"Dose uniformity of loteprednol etabonate (submicron) ophthalmic gel 0.38% compared with prednisolone acetate ophthalmic suspension 1.0%."
  • Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.